5-Nitro-2-Phenylpropylaminobenzoic Acid [Nppb]

5-Nitro-2-Phenylpropylaminobenzoic Acid [Nppb]

SCHEMBL159244

O=C(O)c1cc([N+](=O)[O-])ccc1NCCCc1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 1.00
CDK2 P24941 5/20 1.00
KMT2A Q03164 4/20 1.00
MEN1 O00255 3/20 1.00
NPC1 O15118 2/20 1.00
ALDH1A1 P00352 2/20 1.00
TRPA1 O75762 1/20 1.00
LMNA P02545 1/20 1.00
CYP1A2 P05177 1/20 1.00
CYP2C9 P11712 1/20 1.00
TSHR P16473 1/20 1.00
MAPK1 P28482 1/20 1.00
THPO P40225 1/20 1.00
BLM P54132 1/20 1.00
PMP22 Q01453 1/20 1.00
HSD17B10 Q99714 1/20 1.00
HDAC6 Q9UBN7 1/20 1.00
GAA P10253 1/20 0.73
PKM P14618 1/20 0.70
PLA2G1B P04054 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
5-Nitro-2-Phenylpropylaminobenzoic Acid [Nppb] SCHEMBL29375101 1.00 MAPT (1.00) MAPTCDK2KMT2AMEN1NPC1
SCHEMBL4217741 0.96 MAPT (0.93) MAPTCDK2KMT2AMEN1NPC1
SCHEMBL3029764 0.92 MAPT (1.00) MAPTCDK2KMT2AMEN1NPC1
5-Nitro-2-Phenylpropylaminobenzoic Acid [Nppb] SCHEMBL7821604 0.90 MAPT (0.82) MAPTCDK2KMT2AMEN1NPC1
SCHEMBL6374917 0.90 MAPT (0.82) MAPTCDK2KMT2AMEN1NPC1
SCHEMBL14280729 0.87 CDK2 (0.77) MAPTCDK2KMT2AMEN1NPC1
SCHEMBL4212246 0.84 MAPT (1.00) MAPTCDK2KMT2AMEN1NPC1
SCHEMBL3843127 0.82 KMT2A (0.71) MAPTCDK2KMT2AMEN1NPC1
SCHEMBL27577353 0.82 MAPT (0.69) MAPTCDK2KMT2AMEN1NPC1
SCHEMBL4198828 0.81 MAPT (0.80) MAPTCDK2KMT2AMEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2186 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4744663-A2 SKIN COMPOSITION Eaderm Co., Ltd. (JP) 2026-05-20 EP claimed
US-20260112450-A1 METHODS FOR SELECTION OF CANCER PATIENTS FOR ANTI-ANGIOGENIC AND IMMUNE CHECKPOINT BLOCKAGE THERAPIES AND COMBINATIONS THEREOF WASHINGTON UNIVERSITY ST LOUIS (US) 2026-04-23 US claimed
US-20260016488-A1 CIRCULATING PROTEIN BIOMARKERS OF NECROTIZING ENTERROCOLITIS UNIV COLORADO REGENTS (US) 2026-01-15 US claimed
US-20250345381-A1 TRADITIONAL CHINESE MEDICINE COMPOSITION FOR TREATING CARDIOVASCULAR AND KIDNEY DISEASES AND METHOD FOR PREPARING SAME BEIJING CAPITALBIO PHARMA CO LTD (CN) 2025-11-13 US claimed
US-12447096-B1 Massage roller Guangdong Transcontinental Technology Co., Ltd. (CN) 2025-10-21 US claimed
US-20250320458-A1 CARDIOMYOCYTE SUBTYPES AND METHODS OF MAKING AND USING UNIV HEALTH NETWORK (CA) 2025-10-16 US claimed
US-20250312336-A1 Compositions And Methods For Treating Cancer With Calcium Channel Inhibitors INSTITUTE FOR CANCER RES D/B/A THE RES INSTITUTE OF FOX CHASE CANCER CENTER (US) 2025-10-09 US claimed
US-20250297321-A1 METHOD FOR DETECTING METABOLIC REPROGRAMING OF CANCER TOWARDS FATTY ACIDS METABOLISM INST NAT SANTE RECH MED (FR) 2025-09-25 US claimed
US-20250161330-A1 METHODS OF MEDICAL TREATMENT WITH SUR1-TRPM4 CHANNEL INHIBITORS REMEDY PHARMACEUTICALS, INC. (US) 2025-05-22 US claimed
US-20250140828-A1 METHOD OF PROCESSING POSITIVE ELECTRODE ACTIVE MATERIAL PARTICLES, AND POSITIVE ELECTRODE ACTIVE MATERIAL AND NON-AQUEOUS ELECTROLYTE SECONDARY BATTERY USING SAME BASF TODA BATTERY MATERIALS, LLC (JP) 2025-05-01 US claimed
EP-1284729-A1 A(BETA)42 LOWERING AGENTS MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2003-02-26 EP claimed
US-20020128319-A1 Abeta 42 lowering agents MYREXIS, INC. 2002-09-12 US claimed
US-20020065325-A1 Use of CLC3 chloride channel blockers to modulate vascular tone UNIVERSITY OF IOWA RESEARCH FOUNDATION 2002-05-30 US claimed
WO-2001078721-A1 Aβ42 LOWERING AGENTS MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2001-10-25 WO claimed
US-6187756-B1 Composition and methods for treatment of neurological disorders and neurodegenerative diseases THE MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2001-02-13 US claimed
EP-0713904-B1 Process for treating titanium dioxide pigments, titanium dioxide pigment and its use in papermaking MILLENNIUM INORGANIC CHEM (FR) 2000-07-26 EP claimed
US-5705530-A SIDE EFFECT REDUCTION; GLAUCOMA TREATMENT ALLERGAN (US) 1998-01-06 US claimed
EP-0786994-A2 USE OF CHLORIDE CHANNEL BLOCKERS FOR REDUCING INTRAOCULAR PRESSURE Allergan (US) 1997-08-06 EP claimed
US-5559151-A Method for reducing intraocular pressure in the mammalian eye by administration of chloride channel blockers ALLERGAN (US) 1996-09-24 US claimed
WO-1996016647-A2 USE OF CHLORIDE CHANNEL BLOCKERS FOR REDUCING INTRAOCULAR PRESSURE ALLERGAN (US) 1996-06-06 WO claimed